Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study-Reference-Cited by-同舟云学术

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study

Published:2013-07 Issue:1 Volume:81 Page:77-83
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Morabito Alessandro,Gebbia Vittorio,Di Maio Massimo,Cinieri Saverio,Viganò Maria Grazia,Bianco Roberto,Barbera Santi,Cavanna Luigi,De Marinis Filippo,Montesarchio Vincenzo,Costanzo Raffaele,Sandomenico Claudia,Montanino Agnese,Mancuso Gianfranco,Russo Paolo,Nacci Angelo,Giordano Pasqualina,Daniele Gennaro,Piccirillo Maria Carmela,Rocco Gaetano,Gridelli Cesare,Gallo Ciro,Perrone Francesco

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience;Albain;J Clin Oncol,1991

2. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients;Paesmans;J Clin Oncol,1995

3. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel;Gridelli;Ann Oncol,2004

4. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials;Non-small-cell Lung Cancer Collaborative Group;Br Med J,1995

5. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials;ESMO Open;2024-03

2. A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2;eClinicalMedicine;2023-12

3. International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease;Translational Lung Cancer Research;2023-08

4. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status;Cochrane Database of Systematic Reviews;2023-07-07

5. Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics;BMC Cancer;2023-05-19